The abstract is read at the publisher; the summary is JClub's.
PF-08052667, an integrin β6–targeted antibody-drug conjugate for intravesical dosing in non-muscle-invasive bladder cancer, shows enhanced in vivo efficacy with minimal systemic exposure and no systemic toxicity.
- Why it matters: Non-muscle-invasive bladder cancer makes up 75% of new bladder cancer diagnoses, and despite BCG’s long-standing role, recurrence and treatment failure remain common.
- What they did: The study developed PF-08052667, an IB6-directed ADC using a glucuronide linker and an average of 8 monomethyl auristatin E molecules per antibody, and tested intravesical delivery with bladder prewash to improve tissue delivery.
- The result: Administering PF-08052667 after bladder prewash improved in vivo efficacy while keeping systemic exposure low, supporting its evaluation in an ongoing phase I trial in BCG-unresponsive and BCG-exposed NMIBC (NCT07206225).
The findingWhy it mattersWhat they didThe result
AI summary of the abstract · may contain errors · not medical advice · read the paper.